Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PRMT5 | O14744 | 1/20 | 0.33 |
| ▸ | WDR77 | Q9BQA1 | 1/20 | 0.33 |
| ▸ | NPC1 | O15118 | 2/20 | 0.33 |
| ▸ | RAB9A | P51151 | 2/20 | 0.33 |
| ▸ | MAPT | P10636 | 1/20 | 0.33 |
| ▸ | GRIN1 | Q05586 | 3/20 | 0.32 |
| ▸ | GRIN2B | Q13224 | 3/20 | 0.32 |
| ▸ | HDAC6 | Q9UBN7 | 4/20 | 0.31 |
| ▸ | USP36 | Q9P275 | 2/20 | 0.31 |
| ▸ | LMNA | P02545 | 1/20 | 0.31 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.31 |
| ▸ | CASP3 | P42574 | 1/20 | 0.31 |
| ▸ | ATM | Q13315 | 1/20 | 0.31 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.31 |
| ▸ | SENP8 | Q96LD8 | 1/20 | 0.31 |
| ▸ | SENP7 | Q9BQF6 | 1/20 | 0.31 |
| ▸ | SENP6 | Q9GZR1 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL22169042 | 0.83 | PRMT5 (0.33) | PRMT5WDR77GRIN1GRIN2BHDAC6 | |
| SCHEMBL19251170 | 0.80 | CYP11B1 (0.38) | NPC1RAB9AMAPT | |
| SCHEMBL18746248 | 0.74 | NPC1 (0.53) | NPC1RAB9AMAPTMAPK1 | |
| SCHEMBL23616337 | 0.74 | CCR6 (0.32) | NPC1RAB9AMAPT | |
| SCHEMBL21791646 | 0.74 | CCR6 (0.32) | NPC1RAB9AMAPT | |
| SCHEMBL17828152 | 0.73 | GRIN1 (0.41) | PRMT5WDR77GRIN1GRIN2B | |
| SCHEMBL22905259 | 0.72 | GRIN1 (0.39) | PRMT5WDR77GRIN1GRIN2BHDAC6 | |
| SCHEMBL20993134 | 0.72 | CYP11B2 (0.36) | — | |
| SCHEMBL19251551 | 0.72 | HCAR2 (0.34) | NPC1RAB9AMAPTLMNAMAPK1 | |
| SCHEMBL24656387 | 0.71 | CYP11B1 (0.32) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11028068-B2 | Somatostatin modulators and uses thereof | Crinetics Pharmaceuticals, Inc. (US) | 2021-06-08 | — | — | US | disclosed |
| US-20200207737-A1 | SOMATASTATIN MODULATORS AND USES THEREOF | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2020-07-02 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20200207737-A1 | SOMATASTATIN MODULATORS AND USES THEREOF | SSTR5, SSTR2, SSTR4 | PRMT5 3456/4885WDR77 3954/4885NPC1 193/4885 |
| US-11028068-B2 | Somatostatin modulators and uses thereof | SSTR5, SSTR2, SSTR4 | PRMT5 1747/4885WDR77 3960/4885NPC1 1700/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.